The first review of the micropharmaceutical hydro bromochloric right meschafin tablets

Hydro bromonate right meschafin tablets for the cough type of over-the-counter drugs, belong to class A over-the-counter drugs, suitable for dry cough, including upper respiratory tract infections (such as colds and pharyngitis), bronchitis and other coughs caused by the coughHydro bromoacid right meschafin is a central cough medicine, which can inhibit the extension of the brain cough center and produce coughing effect, its coughing effect is equal to or slightly stronger with codeineGeneral therapeutic dosedoes do not inhibit breathing, long-term use of non-addictive and tolerable1956 by the Fda as an over-the-counter drug, and the FDA was called "the safest of modern" central cough medicine; Drug users range from children to the elderlyright meschafen is one of the four kinds of anti-cough medicine that does not contain compound sputum medicine in the 2019 health insurance catalog, minet China city public hospital chemical drug terminal competition pattern database shows that the 2018 sales of right meschafin in the 2019 health insurance catalog does not contain compound sputum medicine in the first place in the cough medicineannouncement shows that the public pharmaceutical industry has carried out a consistent evaluation of more than 10 varieties, in addition to the transfined sultry tablets, isobiabic tablets, cephalosporine capsules and hydrobromicacid saffre, as well as hydrochloric acid ethyl butanol tablets, ribavirin tablets, Gretzit tablets and other 6 varieties have been subject to the consistency evaluation of generic drugs CDE, in the review and approvalSource: Public Health Pharmaceuticals Announcement Finishing: Blue